Reinach, Switzerland
Reinach, Switzerland

Time filter

Source Type

The present invention is directed to a novel method for the production of 5-epi--vetivone and its use as fragrance or fragrance component.


News Article | June 12, 2017
Site: www.businesswire.com

REINACH, Switzerland--(BUSINESS WIRE)--Evolva (SIX: EVE) announces that Scott Fabro will join Evolva early July and shortly thereafter take over as Chief Commercial Officer, succeeding Luc Gruner. Scott has broad executive experience in various marketing functions in the food industry including ACH Foods, Kerry and Cargill. Most recently he has been Vice-President of ingredient sales at Sweet Harvest Foods. Scott brings extensive knowledge and 27 years of experience in the area of value-added ingredients. Scott’s career highlights include leading ACH (Humko Specialty Powders) where he commercialised NutriSperse® nutritional beverage bases and a unique vitamin E. At Kerry he successfully led the Aromont® culinary, nutritional lipids and specialty powders businesses. While at Cargill he led the commercial strategy for Omega- 3, Beta-glucans, Truvia® ingredient stevia, ViaTech® stevia and led the commercial strategy on EverSweet™ with Evolva. “Developing market demand for new ingredients is what drives me. It is the delivering of a better solution, addressing a problem and then seeing it come together is what is so exciting. I am pleased at the opportunity to join Evolva, a firm committed to providing beneficial ingredients to help people,” Scott Fabro said. Luc Gruner is expected to remain fully engaged in Evolva’s sales and marketing team for some years after the transition, which is scheduled to be completed by September 2017. After this period Luc (born 1952) is expecting to retire. Scott Fabro (born 1964) has a Bachelor’s degree in Marketing from the University of Wisconsin-River Falls. Evolva solves the supply chain issues of nature through a 21st century mix of biotechnology and brewing. We develop, make and sell natural ingredients that provide significant benefits to people in daily life, but whose supply chain issues have limited their use until now. Our flagship ingredients are stevia, nootkatone and resveratrol, but we work on many more, both on our own behalf and with others. To make our world sustainable requires nature and technology to work together as one, and our aim is to play a (small) part in achieving this transformation. We operate internationally. For more information see www.evolva.com. Questions about our approach? Have a look at our video. This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.


Provided are modified santalene synthase polypeptides, nucleic acid molecules encoding the modified santalene synthase polypeptides, and methods of using the modified santalene synthase polypeptides. The modified santalene synthase polypeptides include those that catalyze production of increased levels of terpenes or altered profiles thereof or both.


News Article | July 7, 2017
Site: www.businesswire.com

REINACH, Switzerland--(BUSINESS WIRE)--Evolva (SIX: EVE) today announces the departure of CEO Neil Goldsmith and his succession by the current Chief Operating Officer (COO), Simon Waddington. Since co-founding Evolva, Neil Goldsmith has been instrumental in Evolva’s development over the last thirteen years, moving the company from a pharmaceutical oriented biotech start-up to a listed business developing and selling specialty ingredients for health, wellness and nutrition markets. Neil’s entrepreneurial approach has led to the launch by Evolva of products such as nootkatone and resveratrol, and the advancement of best-tasting stevia products to an anticipated launch in 2018, as communicated earlier this year. Evolva’s Board and executive management have recently determined that the near-term focus needs to be on growing the market opportunity for Evolva’s products and delivering attractive margins. This more focused approach is not a natural fit with Neil’s entrepreneurial strengths, something recognized by both Neil and the Board. As a consequence Neil and the Board have mutually agreed that Neil will step down as CEO and member of the Evolva Board with immediate effect. Neil will be succeeded by Simon Waddington, currently COO of Evolva. Simon had previously been the CEO of Abunda Inc. until its acquisition by Evolva in 2011 upon which he joined the management team. His background and experience is ideally suited to the next phase of Evolva’s evolution. Gerard Hoetmer, Chairman of Evolva’s Board of Directors, said “On behalf of the whole Board, I would like to thank Neil for all his efforts to bring Evolva to where it is today. We are confident that under Simon’s leadership the next steps in the transformation of Evolva to a product-based business can be made. More information on the transformation will be shared at the half-year results announcement on August 14th.” About Evolva Evolva solves the supply chain issues of nature through a 21st century mix of biotechnology and brewing. We develop, make and sell natural ingredients that provide significant benefits to people in daily life, but whose supply chain issues have limited their use until now. Our flagship ingredients are stevia, nootkatone and resveratrol, but we work on many more, both on our own behalf and with others. To make our world sustainable requires nature and technology to work together as one, and our aim is to play a (small) part in achieving this transformation. We operate internationally. For more information see www.evolva.com. Questions about our approach? Have a look at our video. This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.


News Article | December 19, 2016
Site: www.businesswire.com

REINACH, Switzerland--(BUSINESS WIRE)--Evolva (SIX:EVE) announces that it has received a Notice of Allowance for a pivotal patent application (US 2013/0171328) from the US Patent & Trademark Office covering the most commercially viable production method for manufacturing the best-tasting steviol glycosides. This grant is expected to occur early 2017. Of particular commercial importance, this patent protects key steps in the production of rebaudioside A (Reb A), rebaudioside D (Reb D), and rebaudioside M (Reb M) by a number of production methods including fermentation, bioconversion or other approaches. Evolva was the first company to identify and characterise the enzymes for key steps in the Reb A, Reb D and Reb M biosynthesis pathways. Including this most recent patent, Evolva now has 6 granted and 69 pending applications around the world (including 10 in the US and 5 in Europe) related to production of steviol glycosides by various methods including fermentation, bioconversion or in plants. In May, Evolva was granted a European patent (EP2742142) that enables organisms to express highly attractive pathways for producing steviol glycosides. Evolva and Cargill have an exclusive collaboration on the production and commercialisation of stevia sweeteners by fermentation, and are co-developing the next-generation stevia sweetener, EverSweetTM, which is a combination of Reb D and Reb M. Evolva will be providing a more general update on the status of its stevia program and collaboration in the first half of January 2017. Evolva solves the supply chain issues of nature through a 21st century mix of biotechnology and brewing. We develop, make and sell natural ingredients that provide significant benefits to people in daily life, but whose supply chain issues have limited their use until now. Our flagship ingredients are stevia, nootkatone and resveratrol, but we work on many more, both on our own behalf and with others. To make our world sustainable requires nature and technology to work together as one, and our aim is to play a (small) part in achieving this transformation. We operate internationally. For more information see www.evolva.com. Questions about our approach? Have a look at our video. This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.


The present invention is directed to a recombinant cell that produces valencene and aristolochene, wherein the recombinant cell comprises a heterologous nucleic acid that encodes a valencene synthase polypeptide, or a catalytically active fragment thereof; or the recombinant cell comprises a heterologous valencene synthase polypeptide, or a catalytically active fragment thereof. The presnt invention also provides methods of producing valencene and aristolochene using a recombinant cell of the invention and compositions comprising valencene and aristolochene.


News Article | August 21, 2015
Site: www.businesswire.com

REINACH, Switzerland--(BUSINESS WIRE)--Evolva (SIX: EVE) announces the launch of nootkatone, a highly prized citrus flavour and fragrance (F&F) ingredient. By brewing nootkatone from sugar, rather than extracting it from the skin of grapefruits, Evolva’s process allows nootkatone to be made in large amounts in a highly reproducible, contaminant free, sustainable and affordable manner. Evolva has now begun selling nootkatone as a F&F ingredient to food, beverage, personal care, and home care product producers around the world. Nootkatone is a natural aroma ingredient that occurs in grapefruit and certain other plants. It is responsible for the characteristic smell of grapefruit. With a record of demonstrated safety, it is approved in all major countries for use in F&F, and is used in a wide range of foods, drinks, and skin care products. However, until now, its use has been limited by its high price, limited supply, product quality, and other factors. But nootkatone’s commercial prospects go significantly beyond F&F. In both laboratory and field studies, nootkatone has demonstrated excellent activity against biting and nuisance pests, notably the ticks that are responsible for spreading Lyme disease , but also mosquitoes, head lice, bed bugs and other pests. Earlier this year Evolva therefore submitted a request to the US Environmental Protection Agency (EPA) to classify nootkatone as a biochemical pesticide active ingredient (a subcategory of biopesticide). Such a classification allows for a potentially expedited process for registration of nootkatone for use against pests. Evolva received approval of this request on 19th August, and will now engage in an estimated 2-3 years of regulatory work to get nootkatone approved as an insect and tick repellent in the USA. Evolva is also investigating other geographies. Nootkatone’s revenue and bottom line impact on Evolva will initially be modest and the launch does not affect Evolva’s financial projections for 2015. Revenues and net income are expected to increase significantly from 2016 onwards. Until final EPA approval is obtained, all revenues in the USA at least will come from F&F applications. “Nootkatone is one of Evolva’s most exciting products, ”Evolva CEO Neil Goldsmith said. “Since we are committed to improving public health through better functional ingredients, we are doing our part to ensure that nootkatone reaches its full potential—responsibly, but expeditiously.” Evolva is a pioneer and global leader in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. Evolva’s products include stevia, resveratrol, vanillin, nootkatone and saffron. As well as developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them with a competitive edge and sharing in the returns they make. For more information see www.evolva.com. Questions about our fermentation approach? Have a look at our video. Information about the EPA classification system for biopesticides can be found here. Most people develop Lyme disease from the bite of an immature tick, which is tiny (less than 2 mm across), difficult to see, and as a result often goes completely unnoticed. Information about ticks and how to identify them can be found here. Recent information about the spread of Lyme Disease in the USA can be found here. Information from the US Centers for Disease Control and Prevention on tick repellents including nootkatone can be found here. This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.


MINNEAPOLIS & REINACH, Switzerland--(BUSINESS WIRE)--Evolva and Cargill have agreed to begin the engineering phase for converting an existing Cargill manufacturing facility to produce next-generation stevia sweeteners (steviol glycosides). The ingredients are expected to be commercially available in 2016. Stevia-based sweeteners are highly sought-after natural, zero-calorie sweeteners. However, their broader use is currently constrained by their taste at high usage levels, which can be bitter or have an after-taste. Certain stevia sweetener molecules such as Reb D and Reb M do not have this problem, but, because they only make up a tiny portion of the plant’s leaf (much less than 1 percent), it is prohibitively costly to obtain them from the stevia plant. Fermentation removes these constraints and should allow a dramatic expansion in the use of next generation stevia sweeteners, allowing food and beverage producers to create new classes of lower calorie products that taste great and are affordable to all. These sweeteners will be produced in a Cargill fermentation system in Blair, Nebraska. Using a larger existing facility gives the companies the flexibility to expand rapidly and cost-effectively to meet commercial demand. Under terms of the 2013 joint development agreement between the two companies, Evolva received an option to obtain up to a 45% stake in the business to commercialize the sweeteners. Evolva has informed Cargill that it intends to exercise this 45% option, subject to final terms being agreed between the two companies. Total investment by Cargill and Evolva in the engineering phase will be USD 3 million. Evolva does not expect to incur further costs relating to the option exercise before the final agreement is in place, which is expected to be in the second half of 2015. Upon signing the final agreement Evolva anticipates that it will need to invest low tens of millions USD through 2017. Evolva is exploring various financing options in this context. Per the 2013 agreement, if Evolva and Cargill cannot finalize terms on the option exercise, Evolva will receive royalty payments from global sales of the steviol glycoside products; these royalties will scale from mid-single digit to low double-digit percentages as a function of sales volume and other parameters. In this circumstance Cargill would repay Evolva’s share of the engineering costs. Evolva CEO Neil Goldsmith commented, “We have been delighted by our close cooperation with Cargill over the past two-plus years. The decision to commence engineering work reflects our mutual desire and commitment to bring great tasting, cost-effective sweeteners to the market as soon as possible. While there remain risks which could impact the timing of the final product launch and consumer uptake, we are confident in our joint progress.” "Adding new production capabilities at our Cargill Blair facility fits strategically with our overall growth plan and is an exciting and necessary step as we prepare for the commercialization of a next-generation sweetener,” stated David Henstrom, vice president for Health Ingredients at Cargill. “This sweetener will offer a new, delicious choice for reduced and zero-calorie food and beverages." Cargill provides food, agriculture, financial and industrial products and services to the world. Together with farmers, customers, governments and communities, we help people thrive by applying our insights and nearly 150 years of experience. We have 145,000 employees in 67 countries who are committed to feeding the world in a responsible way, reducing environmental impact and improving the communities where we live and work. For more information, visit Cargill.com and our News Center. Evolva is a pioneer and global leader in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. Evolva’s products include stevia, vanillin, saffron and resveratrol. As well as developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them with a competitive edge and sharing in the returns they make. For more information see www.evolva.com. Questions about our fermentation approach? Have a look at our video. This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.


REINACH, Switzerland--(BUSINESS WIRE)--Evolva (SIX: EVE) today announces the US government’s approval of the transfer (“novation”) of the GC-072 contract to Emergent BioSolutions Inc. (NYSE: EBS). This triggers a payment of USD 4 million to Evolva, following an initial upfront payment of USD 1.5 million in December 2014. This does not change the revenue guidance for 2015. In December 2014, Emergent acquired Evolva’s anti-bacterial programme, the EV-035 series in a transaction worth up to USD 70.5 million plus royalties. The lead compound in the EV-035 series is the broad-spectrum antibiotic GC-072, which is being developed with US government biodefense funding. Emergent will now have full responsibility for this contract. Evolva is a pioneer and global leader in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. Evolva’s products include stevia, resveratrol, vanillin, nootkatone and saffron. As well as developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them with a competitive edge and sharing in the returns they make. For more information see www.evolva.com. Questions about our fermentation approach? Have a look at our video. This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.


MINNEAPOLIS & REINACH, Switzerland--(BUSINESS WIRE)--Evolva and Cargill have agreed to begin the engineering phase for converting an existing Cargill manufacturing facility to produce next-generation stevia sweeteners (steviol glycosides). The ingredients are expected to be commercially available in 2016. Stevia-based sweeteners are highly sought-after natural, zero-calorie sweeteners. However, their broader use is currently constrained by their taste at high usage levels, which can be bitter or have an after-taste. Certain stevia sweetener molecules such as Reb D and Reb M do not have this problem, but, because they only make up a tiny portion of the plant’s leaf (much less than 1 percent), it is prohibitively costly to obtain them from the stevia plant. Fermentation removes these constraints and should allow a dramatic expansion in the use of next generation stevia sweeteners, allowing food and beverage producers to create new classes of lower calorie products that taste great and are affordable to all. These sweeteners will be produced in a Cargill fermentation system in Blair, Nebraska. Using a larger existing facility gives the companies the flexibility to expand rapidly and cost-effectively to meet commercial demand. Under terms of the 2013 joint development agreement between the two companies, Evolva received an option to obtain up to a 45% stake in the business to commercialize the sweeteners. Evolva has informed Cargill that it intends to exercise this 45% option, subject to final terms being agreed between the two companies. Total investment by Cargill and Evolva in the engineering phase will be USD 3 million. Evolva does not expect to incur further costs relating to the option exercise before the final agreement is in place, which is expected to be in the second half of 2015. Upon signing the final agreement Evolva anticipates that it will need to invest low tens of millions USD through 2017. Evolva is exploring various financing options in this context. Per the 2013 agreement, if Evolva and Cargill cannot finalize terms on the option exercise, Evolva will receive royalty payments from global sales of the steviol glycoside products; these royalties will scale from mid-single digit to low double-digit percentages as a function of sales volume and other parameters. In this circumstance Cargill would repay Evolva’s share of the engineering costs. Evolva CEO Neil Goldsmith commented, “We have been delighted by our close cooperation with Cargill over the past two-plus years. The decision to commence engineering work reflects our mutual desire and commitment to bring great tasting, cost-effective sweeteners to the market as soon as possible. While there remain risks which could impact the timing of the final product launch and consumer uptake, we are confident in our joint progress.” "Adding new production capabilities at our Cargill Blair facility fits strategically with our overall growth plan and is an exciting and necessary step as we prepare for the commercialization of a next-generation sweetener,” stated David Henstrom, vice president for Health Ingredients at Cargill. “This sweetener will offer a new, delicious choice for reduced and zero-calorie food and beverages." Cargill provides food, agriculture, financial and industrial products and services to the world. Together with farmers, customers, governments and communities, we help people thrive by applying our insights and nearly 150 years of experience. We have 145,000 employees in 67 countries who are committed to feeding the world in a responsible way, reducing environmental impact and improving the communities where we live and work. For more information, visit Cargill.com and our News Center. Evolva is a pioneer and global leader in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. Evolva’s products include stevia, vanillin, saffron and resveratrol. As well as developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them with a competitive edge and sharing in the returns they make. For more information see www.evolva.com. Questions about our fermentation approach? Have a look at our video. This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Loading Evolva Inc. collaborators
Loading Evolva Inc. collaborators